Accession Therapeutics Limited
Lucie Bouard began their work experience in 2012 with an internship at Aelred. Lucie then had another internship in 2013 at Glenmark Pharmaceuticals. In 2014, they joined Immunocore Limited as a Scientist and later became a Senior Scientist in 2021. Lucie is currently working as a Senior Scientist at Accession Therapeutics Limited, starting in 2022.
Lucie Bouard pursued their education at ENSTBB Bordeaux INP from 2011 to 2014, where they obtained a Master's degree in Biotechnology. Prior to that, from 2009 to 2011, they completed their Bachelor's degree in Biochemistry and Molecular Biology at Université Paris Cité.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.